Saratov JOURNAL of Medical and Scientific Research
Home

Estimates for effectiveness of intravitreal aflibercept in the treatment of diabetic macular edema

Year: 2021, volume 17 Issue: №3 Pages: 655-659
Heading: Тhematic supplement Article type: Original article
Authors: Sinitsyna V.I., Batishcheva Yu.S., Gileva E.M., Gubareva N.N., Nugaeva N.R., Barabanova L.S.
Organization: Saratov State Medical University, University Clinical Hospital №2 (Clinic of Eye Diseases)
Summary:

Purpose: to estimate the effectiveness of intravitreal aflibercept (IA) in the treatment of diabetic macular edema (DME) in patients with varying degrees of compensation for carbohydrate metabolism. Material and Methods. The study involved 63 patients (63 eyes) with proliferative diabetic retinopathy complicated by diabetic macular edema. Two groups were formed. In group I (n=43), the level of glycated hemoglobin (HbA1c) remained within the normal range during the entire observation period (HbA1c<7.5%). In group II (n=20), the HbA1c level was increased during the year (HbA1c>7.5%). During the initial examination, there were no significant differences between groups I and II in terms of maximum corrected visual acuity (MCVA) and retinal thickness in the center (RTC) (p=0.1).The patients received five intravitreal injections of aflibercept (2 mg). Optical coherence tomograph Spectralis ОСТ (Heidelberg Engeneering, Germany) was used to determine the thickness of the retina. Results. After the fifth IA, significant differences were found between MCVA(p=0.02) and RTC (p=0.03) among groups I and II. Group I patients showed an increase in MCVA from0.22±0.08to0.53±0.21; in group II from 0.18±0.2to 0.32±0.18, and a decrease in MCVAfrom456±112to 304±92 in group I and 480±109 to 376±98 in group II. Conclusion. The results of the study confirm the clinical efficacy of IA in the treatment of DME. Due to the treatment, visual acuity improves, the thickness of the retina decreases, and the outflow of intraretinal fluid is activated. In patients with impaired carbohydrate metabolism, the dynamics of a decrease in RTC and an increase in MCVA are less pronounced.

Keywords: aflibercept, diabetic macular edema

Bibliography:
1. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-63. DOI: 10.1001/archopht. 122.4.552.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53. DOI: 10.2337/diacare. 27.5.1047.
3. Amirov AN, Abdulaeva EA, Minkhuzina EN. Diabetic macular edema: epidemiology, pathogenesis, diagnosis, clinical picture, treatment. Kazan Medical Journal 2015; 96 (1): 70-6.
4. Zhang X, Zeng Н, Bao S, et al. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014; 4: 27. DOI: 10.1186/2045-3701-4-27.
5. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010; 59 (5): 1244-53. DOI: 10.2337/db09-1216.
6. Avetisov SE, ed. Diseases of the fundus. Moscow: MEDpress-inform, 2008; p. 42-3.
7. Ciombor КК, Berlin J. Aflibercept — A decoy VEGF receptor. Curr Oncol Rep 2014; 16:368. DOI: 10.1007/sl 1912-013-0368-7.
8. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237: 185-222.
9. Korobelnik J, Do D, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121 (11): 2247-54.
10. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology 2016; 123 (11): 2376-85.

AttachmentSize
2021_03-2_655-659.pdf657.48 KB
All articles of the authors: Barabanova L.S.

No votes yet